This site is intended for healthcare professionals only.
Log in
Menu

Rapcabtagene autoleucel my be a viable frontline option in high-risk LBCL

  • ASH 2025
  • Video interview
Speaker: Jason Westin
The University of Texas MD Anderson Cancer Center, Texas, USA
Dr Jason Westin shares the latest findings on rapcabtagene autoleucel for the treatment of patients with high-risk large B-cell lymphoma autologous in the first-line setting.

ASH2025 Congress; Orlando, Florida, USA: 6-9 December

Https://www.hematology.org/meetings/annual-meeting

Log in

Like this content?

Share with a colleague

Before you go...

We want to hear from you! Share your quick feedback

By providing my email I consent to receive e-alerts from Springer Health+ IME pertinent to my area of interest. I can withdraw my consent at any time by contacting [email protected] or via the ‘unsubscribe’ link included in any email communications.

No, thanks (don't show this again)

Register for alerts

Complete the short registration form to be contacted when new learning content is made available, including ASH conference coverage, an “experts in conversation” webcast and free downloadable practice aid.

Log in to sign up for alerts